DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72628
Title:
DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial.
Authors:
Payne, Miranda; Ellis, Paul A; Dunlop, D; Ranson, Malcolm R; Danson, Sarah; Schacter, Lee; Talbot, Denis
Abstract:
INTRODUCTION: This prospective, open-label, non-randomized, multi-institutional phase II study was undertaken to assess the antitumor activity and safety of docosahexaenoic acid-paclitaxel (Taxoprexin) as first-line treatment of patients with advanced non-small cell lung cancer. PATIENTS AND METHODS: Chemotherapy-naive patients were eligible if they had measurable stage IIIB or IV non-small cell lung cancer. Forty-four patients received docosahexaenoic acid-paclitaxel by intravenous infusion every 21 days. Two doses were evaluated: 1100 mg/m and 900 mg/m. Patients were monitored for toxicity and tumor response. RESULTS: Patients received between one and seven (median, two) cycles of treatment. Twenty-eight courses were administered in the cohort starting at 1100 mg/m and 109 courses at 900 mg/m. The starting dose was reduced to 900 mg/m because of toxicity in the first 13 patients. Subsequently, the most severe toxicity was neutropenia (grade III/IV in 68% of patients treated with 900 mg/m). Forty patients were eligible for assessment of tumor response. Two partial responses (4.5%) were documented, and a further 16 patients (36.4%) had stable disease based on an intent-to-treat analysis. The median duration of survival for all patients was 243 days (range, 154-359) and the 1-year survival rate was 35%. CONCLUSION: As a single-agent, docosahexaenoic acid-paclitaxel has little activity in patients with advanced non-small cell lung cancer, with 18 patients (40.1%) achieving either stable disease or a partial response after treatment. Despite the low objective response rate, treatment was associated with survival comparable to that seen with standard platinum-based combination chemotherapy. The dose-limiting toxicity was myelosuppression.
Affiliation:
Cancer Research UK Oxford Cancer Centre, Oxford, UK.
Citation:
DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial. 2006, 1 (9):984-90 J Thorac Oncol
Journal:
Journal of Thoracic Oncology
Issue Date:
Nov-2006
URI:
http://hdl.handle.net/10541/72628
PubMed ID:
17409983
Type:
Article
Language:
en
ISSN:
1556-1380
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorPayne, Miranda-
dc.contributor.authorEllis, Paul A-
dc.contributor.authorDunlop, D-
dc.contributor.authorRanson, Malcolm R-
dc.contributor.authorDanson, Sarah-
dc.contributor.authorSchacter, Lee-
dc.contributor.authorTalbot, Denis-
dc.date.accessioned2009-07-06T16:00:39Z-
dc.date.available2009-07-06T16:00:39Z-
dc.date.issued2006-11-
dc.identifier.citationDHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial. 2006, 1 (9):984-90 J Thorac Oncolen
dc.identifier.issn1556-1380-
dc.identifier.pmid17409983-
dc.identifier.urihttp://hdl.handle.net/10541/72628-
dc.description.abstractINTRODUCTION: This prospective, open-label, non-randomized, multi-institutional phase II study was undertaken to assess the antitumor activity and safety of docosahexaenoic acid-paclitaxel (Taxoprexin) as first-line treatment of patients with advanced non-small cell lung cancer. PATIENTS AND METHODS: Chemotherapy-naive patients were eligible if they had measurable stage IIIB or IV non-small cell lung cancer. Forty-four patients received docosahexaenoic acid-paclitaxel by intravenous infusion every 21 days. Two doses were evaluated: 1100 mg/m and 900 mg/m. Patients were monitored for toxicity and tumor response. RESULTS: Patients received between one and seven (median, two) cycles of treatment. Twenty-eight courses were administered in the cohort starting at 1100 mg/m and 109 courses at 900 mg/m. The starting dose was reduced to 900 mg/m because of toxicity in the first 13 patients. Subsequently, the most severe toxicity was neutropenia (grade III/IV in 68% of patients treated with 900 mg/m). Forty patients were eligible for assessment of tumor response. Two partial responses (4.5%) were documented, and a further 16 patients (36.4%) had stable disease based on an intent-to-treat analysis. The median duration of survival for all patients was 243 days (range, 154-359) and the 1-year survival rate was 35%. CONCLUSION: As a single-agent, docosahexaenoic acid-paclitaxel has little activity in patients with advanced non-small cell lung cancer, with 18 patients (40.1%) achieving either stable disease or a partial response after treatment. Despite the low objective response rate, treatment was associated with survival comparable to that seen with standard platinum-based combination chemotherapy. The dose-limiting toxicity was myelosuppression.en
dc.language.isoenen
dc.subjectCancer Stagingen
dc.subject.meshAdult-
dc.subject.meshAge Factors-
dc.subject.meshAged-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshDisease-Free Survival-
dc.subject.meshDocosahexaenoic Acids-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshDrug Combinations-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHumans-
dc.subject.meshInfusions, Intravenous-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMaximum Tolerated Dose-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshPaclitaxel-
dc.subject.meshPatient Selection-
dc.subject.meshProbability-
dc.subject.meshProspective Studies-
dc.subject.meshRisk Factors-
dc.subject.meshSingle-Blind Method-
dc.subject.meshSurvival Analysis-
dc.titleDHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Oxford Cancer Centre, Oxford, UK.en
dc.identifier.journalJournal of Thoracic Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.